SCHEMBL30816293

SCHEMBL30816293

Cc1cccnc1C(C)(C)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.50
NOS1 P29475 1/20 0.50
NOS2 P35228 1/20 0.50
SSTR4 P31391 1/20 0.43
NPC1 O15118 3/20 0.41
RAB9A P51151 2/20 0.41
PLAU P00749 1/20 0.41
KDM4E B2RXH2 1/20 0.41
L3MBTL1 Q9Y468 3/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 2/20 0.37
CYP2A6 P11509 1/20 0.37
SLC6A2 P23975 1/20 0.37
PDK2 Q15119 1/20 0.37
FDPS P14324 2/20 0.36
CYP3A4 P08684 1/20 0.36
TSHR P16473 1/20 0.36
CYP2C19 P33261 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
HSP90AA1 P07900 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL130124 1.00 NOS3 (0.50) NOS3NOS1NOS2SSTR4NPC1
SCHEMBL77479 0.82 NOS3 (0.48) NOS3NOS1NOS2SSTR4NPC1
SCHEMBL15192976 0.79 SSTR4 (0.39) NOS3NOS1NOS2SSTR4NPC1
SCHEMBL5038676 0.78 ALDH1A1 (0.44) KDM4EL3MBTL1HTTSLC6A2CYP3A4
SCHEMBL1332434 0.78 NOS3 (0.45) NOS3NOS1NOS2SSTR4NPC1
SCHEMBL16252854 0.78 NOS3 (0.50) NOS3NOS1NOS2SSTR4NPC1
SCHEMBL16019426 0.78 NOS3 (0.45) NOS3NOS1NOS2SSTR4NPC1
SCHEMBL129161 0.78 NOS3 (0.41) NOS3NOS1NOS2SSTR4NPC1
SCHEMBL23126660 0.77 ACSS2 (0.36) KDM4EL3MBTL1MAPTHTTCYP3A4
SCHEMBL16836001 0.77 SMN1; SMN2 (0.35) SSTR4KDM4EL3MBTL1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024056016-A1 FREE BASE CRYSTAL FORM OF POLYCYCLIC COMPOUND OF NITROGEN-CONTAINING HETEROCYCLE, AND PREPARATION METHOD THEREFOR 江苏豪森药业集团有限公司 2024-03-21 WO disclosed